Las tecnologías vestibles actuales que incorporan conductos con fluidos a alta presión que deben ser bombeados requieren típicamente una bomba grande y ruidosa que resulta poco práctica (o imposible) de integrar en la ropa. Esto lleva a una contradicción: dispositi …
Ropa con "arterias" cosidas en el tejido Read More »
Algunos planetas, por su cercanía a su estrella, acaban sincronizando su rotación con su traslación de tal modo que siempre tienen un mismo lado expuesto al sol y otro en el que nunca da el sol. Eso puede acarrear una gran diferencia entre la temperatura del lado diurno y la del …
Vida en el terminador de planetas con día y noche perpetuos Read More »
En este Short os hablamos de las series dificultades a las que se enfrentarán los productores de café debido al cambio climático, amenazando su disponibilidad. …
Aurinia Pharmaceuticals Inc. announced promising results from the AURORA Renal Biopsy Sub-Study.
Immunic, Inc. reported positive data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset, vidofludimus calcium, in patients with moderate-to-severe ulcerative colitis .
Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the first-in-human phase I trial of AVA6000.
Addex Therapeutics Ltd announced that it has completed the equity financing transaction entered into on April 3, 2023 with a leading institutional healthcare investor, pursuant to which the Company sold 7,999,998 shares in the form of 1,333,333 American Depositary Shares at a gross purchase price of $0.95 per ADS.
TransCode Therapeutics, Inc. announced that its previously announced sale of Series A Convertible Preferred Stock for an aggregate purchase price of $500,000 will not be consummated after the proposed purchaser advised the Company that it was not prepared to complete the transaction on the terms set forth in the Stock Purchase Agreement signed by the
RELIEF THERAPEUTICS Holding SA announced that Nermeen Varawalla, M.D., Ph.D., chief medical officer, will depart the Company in the second quarter of 2023 to pursue other opportunities.
Relief Therapeutics Announces Executive Leadership Team Change Read More »
Perfuse Therapeutics announced that the US Food and Drug Administration has cleared the Investigational New Drug application for a Phase 1/2a clinical study of PER-001 Intravitreal Implant in patients with glaucoma.
